The sleep apnea implants market is set to grow steadily by 2030 owing to surging number of sleep apnea patients. In addition, rising awareness about sleep apnea disorders and expanding geriatric population with sleep apnea are likely to facilitate market growth through the forecast period.

During the COVID-19 pandemic, the industry witnessed a setback in business operations due to restrictions on movement and a strong focus on developing effective treatments for the coronavirus infection. However, the post-pandemic scenario has fueled market progress as a result of growing awareness pertaining to sleep apnea.

Various government initiatives, along with significant investments by public and private companies in the field, have also boosted consumer interest in the product. For instance, in February 2021, the U.S. FDA approved a tongue muscle stimulation device eXciteOSA that claims to calm mild sleep apnea in the user’s waking hours. The device is the first to improve tongue muscle function during daytime, which can eventually treat tongue movement and prevent obstructive sleep apnea at night.

Notably, major players in the industry are investing in innovations in sleep apnea implant technology, coupled with growth strategies like acquisitions and partnerships, thereby fostering business growth. For instance, in April 2022, Natus Medical Incorporated, a provider of medical treatment solutions, announced that it has inked an agreement to be acquired by Archimed Group, a leading healthcare investment firm, for around $1.2 billion. Under the terms of the agreement, Natus shareholders were set to receive $33.50 in cash for each share.

The sleep apnea implants market has been bifurcated based on end-use, product, indication, and region.

In terms of product, the industry has been divided into palatal implants, bone screw system, phrenic nerve stimulator, and hypoglossal neurostimulation devices. The phrenic nerve stimulator sub-segment registered a valuation of above $24 million in 2021 as a result of increasing adoption of phrenic nerve stimulators for central sleep apnea management.

With regards to indication, the sleep apnea implants market has been split into central sleep apnea and obstructive sleep apnea. The obstructive sleep apnea or OSA sub-segment accounted for over 92% of the market revenue in 2021 attributed to surging awareness regarding obstructive sleep apnea, rising number of disease-affected people, and availability of several treatment alternatives for the condition.

The industry has been segmented based on end-use into ambulatory surgical centers, hospitals, and others. The ambulatory surgical centers sub-segment was valued at around $128 million in 2021 due to the feasible reimbursement coverage and availability of latest surgical technologies that promote patient satisfaction and convenience.

In the regional frame of reference, apart from Europe and North America, the RoW sleep apnea implants market is expected to grow at a CAGR of approximately 19.2% through the study time span. Rising prevalence of sleep apnea, increased adoption of sleep apnea implants, and soaring awareness about the disease are slated to fuel regional market growth in the future.